Beyond its prognostic value across cancers [24–28], existing studies in vivo have shown that tsMHC-II, compared to tsMHC-I, can present a broader range of tumor-associated neoantigens, playing a vital part in reshaping anti-tumor immune microenvironment(TME), activating CD4 + T cell anti-tumor effects by using tumor necrosis factor–α and Fas ligand (FasL), and inducing more stringent environmental pressures for tumor survival evolution [29–31]. The gene discussed is CD4; the disease is neoplasm.